Cogent Biosciences, Inc. (COGT)
33.38
-1.23
(-3.55%)
USD |
NASDAQ |
Mar 20, 16:00
33.40
+0.02
(+0.06%)
After-Hours: 20:00
Cogent Biosciences Research and Development Expense (Quarterly) : 74.38M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Terns Pharmaceuticals, Inc. | 19.92M |
| Nuvalent, Inc. | 67.80M |
| Sarepta Therapeutics, Inc. | 319.50M |
| BridgeBio Pharma, Inc. | 116.42M |
| Mirum Pharmaceuticals, Inc. | 51.03M |